Biodexa Pharmaceuticals (BDRX) Company Report

Analyst Coverage

Research analysts covering Biodexa Pharmaceuticals.

Recent press releases and 8-K filings for BDRX.

Biodexa Pharmaceuticals PLC Licenses Otsuka's OPB-171775 for GIST Treatment

BDRX

New Projects/Investments

Biodexa Pharmaceuticals PLC announced on February 4, 2026, the closing of an exclusive, worldwide (excluding Japan) license with Otsuka Pharmaceutical Co., Ltd. for MTX240 (OPB-171775), a Phase 1-ready molecular glue intended for the treatment of gastrointestinal stromal tumors (GIST).
Under the agreement, Biodexa made an upfront payment to Otsuka and is obligated to pay one-time development and regulatory milestones, along with tiered royalties in the mid-single digits on net sales of licensed products.
MTX240 is designed to address the unmet medical need in GIST patients who develop resistance to conventional tyrosine kinase inhibitors (TKIs), a group representing approximately 10-15% of GIST patients.
The global GIST market is valued at approximately $1.3 billion and is projected to grow 6-10% annually through 2032, with MTX240 benefiting from composition of matter patents extending through 2037.

3 days ago

Biodexa Pharmaceuticals PLC Announces Pricing of Public Offering

BDRX

New Projects/Investments

Biodexa Pharmaceuticals PLC announced the pricing of a best efforts public offering expected to generate approximately $10 million in aggregate gross proceeds.
The offering includes 157,000 ADS Units priced at $3.28 each, and 2,891,781 Pre-Funded Units priced at $3.2799 each.
Each unit comprises two Series L Warrants exercisable at $3.28 per ADS for five years, while Pre-Funded Warrants have an exercise price of $0.0001 per ADS.
The estimated net proceeds of approximately $8.75 million will be used to fund development programs, for working capital, and other general corporate purposes.
The offering is anticipated to close on December 19, 2025.

Dec 18, 2025, 1:40 PM

Biodexa Pharmaceuticals Receives European CTA Approval for Phase 3 Serenta Trial

BDRX

New Projects/Investments

Biodexa Pharmaceuticals PLC announced the approval of a Clinical Trial Application (CTA) by the European Medicines Agency (EMA) for its pivotal Phase 3 Serenta clinical trial of eRapa in patients with familial adenomatous polyposis (FAP).
This approval permits the Serenta trial to proceed in Europe, initially covering sites in Denmark, Germany, the Netherlands, and Spain, with the first European patient expected to be enrolled in 4Q 2025.
The U.S. component of the trial enrolled its first patient in mid-August 2025, and the company estimates an addressable U.S. - European market of $7 billion for this treatment.
The Serenta trial is a randomized, double-blind, placebo-controlled study designed to recruit 168 patients to evaluate the safety and efficacy of eRapa.

Nov 3, 2025, 1:38 PM

Biodexa Pharmaceuticals PLC Announces Interim Results and Operational Progress

BDRX

Earnings

New Projects/Investments

Biodexa Pharmaceuticals PLC reported unaudited interim results for the six months ended June 30, 2025, with a net cash inflow of £2.37 million for the period, bringing the cash balance to £4.04 million as of that date.
The company secured a $35 million Equity Line of Credit (ELOC) in January 2025, from which it had raised $8.56 million in gross proceeds by June 30, 2025.
Operationally, Biodexa advanced its R&D pipeline, notably with the recruitment of the first patients in the pivotal Serenta trial (eRapa in FAP) and obtaining Orphan Drug Designation for eRapa in FAP from the European Commission.
The company reported an accumulated deficit of £154.13 million as of June 30, 2025, and stated that further financing will be required before the second quarter of 2026, highlighting a material uncertainty regarding its ability to continue as a going concern.

Sep 12, 2025, 1:00 PM

Get instant answers from SEC filings, earnings calls & more